These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30548935)

  • 1. Outcome of sirolimus-based immunosuppression, fifteen years post-live-donor kidney transplantation: Single-center experience.
    Hamdy AF; Elhadedy MA; Donia AF; Taha NM; Bakr MA
    Clin Transplant; 2019 Feb; 33(2):e13463. PubMed ID: 30548935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year.
    Mendez R; Gonwa T; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2005 Aug; 80(3):303-9. PubMed ID: 16082323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus.
    Miles CD; Skorupa JY; Sandoz JP; Rigley TH; Nielsen KJ; Stevens RB
    Clin Transplant; 2011; 25(6):898-904. PubMed ID: 21077952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
    Kim J; Park J; Hwang S; Yoo H; Kim K; Park JB; Jang HR; Lee JE; Kim SJ; Kim YG; Kim DJ; Oh HY; Huh W
    Clin Transplant; 2018 Sep; 32(9):e13372. PubMed ID: 30080284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus.
    Rummo OO; Carmellini M; Rostaing L; Oberbauer R; Christiaans MH; Mousson C; Langer RM; Citterio F; Charpentier B; Brown M; Kazeem G; Lehner F;
    Transpl Int; 2017 Jan; 30(1):83-95. PubMed ID: 27754567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
    Weir MR; Pearson TC; Patel A; Peddi VR; Kalil R; Scandling J; Chan L; Baliga P; Melton L; Mulgaonkar S; Waid T; Schaefer H; Youssef N; Anandagoda L; McCollum D; Lawson S; Gordon R
    Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
    Gralla J; Wiseman AC
    Transplantation; 2009 Jun; 87(11):1712-9. PubMed ID: 19502965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
    Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T
    Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation.
    Tedesco-Silva H; Del Carmen Rial M; Cruz Santiago J; Mazzali M; Pacheco-Silva A; Torres R
    Clin Transplant; 2019 Feb; 33(2):e13464. PubMed ID: 30548896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
    Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
    Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis.
    Ciancio G; Burke GW; Gaynor JJ; Ruiz P; Roth D; Kupin W; Rosen A; Miller J
    Transplantation; 2006 Mar; 81(6):845-52. PubMed ID: 16570006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
    Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
    Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
    Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
    J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.